Dendreon Corp fka DNDNQ

[iwfal]

the target of 75% of events is the extreme end of the spectrum, and usually just past the median is reasonable for a survival trial.

This is plain not true. Almost all cancer trials with relatively short time to event use near 75%. Trials with longer times to event can use substantially lower fractions (e.g. MACE trials), but cancer trials are almost always between high 60's and high 70's - with most clustered right near 75%. If you have an exception I'd like to see it.

9902a is among the longer times to event for a cancer trial (median SoC survival of probably 18 months with the new population vs typical cancer trial survival times of 4-12 months), so it is possible the target number of events is as low as high 60's (say 67%). But I'd be very surprised if it were much lower.